Manuel Botana

984 total citations · 1 hit paper
32 papers, 617 citations indexed

About

Manuel Botana is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Manuel Botana has authored 32 papers receiving a total of 617 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Endocrinology, Diabetes and Metabolism, 13 papers in Cardiology and Cardiovascular Medicine and 7 papers in Surgery. Recurrent topics in Manuel Botana's work include Diabetes Treatment and Management (12 papers), Chronic Kidney Disease and Diabetes (6 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (6 papers). Manuel Botana is often cited by papers focused on Diabetes Treatment and Management (12 papers), Chronic Kidney Disease and Diabetes (6 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (6 papers). Manuel Botana collaborates with scholars based in Spain, Portugal and Sweden. Manuel Botana's co-authors include Johan Bodegård, Tiago Taveira‐Gomes, Marcus Thuresson, Avraham Karasik, Navdeep Tangri, Andreas Bollmann, Johan Sundström, Kåre I. Birkeland, Levy Jäger and Patrick B. Mark and has published in prestigious journals such as Diabetes Care, Heart and European Journal of Endocrinology.

In The Last Decade

Manuel Botana

30 papers receiving 606 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study

2022 191 citations Johan Sundström, Johan Bodegård et al. The Lancet Regional Health - Europe profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Manuel Botana Spain	13	204	194	161	79	68	32	617
Gerald Vervoort Netherlands	15	272 1.3×	203 1.0×	187 1.2×	158 2.0×	122 1.8×	21	801
S. J. L. Bakker Netherlands	9	439 2.2×	164 0.8×	111 0.7×	79 1.0×	66 1.0×	10	765
Satoshi Iimuro Japan	12	163 0.8×	196 1.0×	71 0.4×	99 1.3×	40 0.6×	31	542
Ziad Massy France	5	137 0.7×	107 0.6×	181 1.1×	37 0.5×	47 0.7×	11	417
Min Zhuo United States	16	100 0.5×	270 1.4×	215 1.3×	59 0.7×	165 2.4×	38	764
Ewa Król Poland	15	175 0.9×	75 0.4×	190 1.2×	55 0.7×	66 1.0×	61	587
Onofre Vegazo Spain	15	198 1.0×	139 0.7×	67 0.4×	74 0.9×	56 0.8×	21	578
Deborah Anzalone United States	11	265 1.3×	283 1.5×	108 0.7×	73 0.9×	91 1.3×	19	841
P. Hougaard Denmark	6	192 0.9×	348 1.8×	132 0.8×	140 1.8×	90 1.3×	10	818
Elise Gand France	15	146 0.7×	226 1.2×	251 1.6×	81 1.0×	101 1.5×	35	675

Countries citing papers authored by Manuel Botana

Since Specialization

Citations

This map shows the geographic impact of Manuel Botana's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuel Botana with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuel Botana more than expected).

Fields of papers citing papers by Manuel Botana

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manuel Botana. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuel Botana. The network helps show where Manuel Botana may publish in the future.

Co-authorship network of co-authors of Manuel Botana

This figure shows the co-authorship network connecting the top 25 collaborators of Manuel Botana. A scholar is included among the top collaborators of Manuel Botana based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manuel Botana. Manuel Botana is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Vivas, David, Carlos Escobar, Alberto Cordero, et al.. (2024). Uso de nuevas terapias hipolipemiantes en la práctica clínica. Consenso SEC/SEA/SEEN/SEMFYC/SEMERGEN/SEMG/SEN/SEACV/S.E.N.. REC CardioClinics. 59(4). 310–321. 1 indexed citations

2.

Norhammar, Anna, Johan Bodegård, Marc Vanderheyden, et al.. (2023). Prevalence, outcomes and costs of a contemporary, multinational population with heart failure. Heart. 109(7). 548–556. 43 indexed citations

3.

Manito, Nicolás, Carlos Escobar, Beatriz Palacios, et al.. (2022). Risk of outcomes in a Spanish population with heart failure. REC CardioClinics. 57(2). 85–96. 1 indexed citations

4.

Cebrián, Ana, Carlos Escobar, Beatriz Palacios, et al.. (2022). The 2021 European Society of Cardiology Cardiovascular Disease Prevention Guidelines: adding albuminuria to the SCORE scale increases the prevalence of very high/high cardiovascular risk among patients with chronic kidney disease. Clinical Kidney Journal. 15(6). 1204–1208. 11 indexed citations

5.

Arroyo, Roberto Alcázar, Carlos Escobar, Beatriz Palacios, et al.. (2022). Risk of outcomes in a Spanish population with chronic kidney disease. Clinical Kidney Journal. 15(7). 1415–1424. 2 indexed citations

6.

Morales, Cristóbal, et al.. (2022). Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study. Drugs in Context. 11. 1–9. 1 indexed citations

7.

Sundström, Johan, Johan Bodegård, Andreas Bollmann, et al.. (2022). Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study. The Lancet Regional Health - Europe. 20. 100438–100438. 191 indexed citations breakdown →

8.

Botana, Manuel, et al.. (2022). Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review. Diabetes Therapy. 13(S1). 5–17. 6 indexed citations

9.

Morales, Cristóbal, Virginia Bellido, Cristina Tejera Pérez, et al.. (2021). DAPA-RWE: a retrospective multicenter study comparing dapagliflozin and sitagliptin in patients with Type 2 diabetes treated under routine clinical practice in Spain. Journal of Comparative Effectiveness Research. 10(10). 815–821. 2 indexed citations

10.

Escobar, Carlos, Beatriz Palacios, Margarita Capel, et al.. (2021). Epidemiology, clinical profile, management, and two-year risk complications among patients with chronic kidney disease in Spain. Nefrología (English Edition). 41(6). 670–688. 15 indexed citations

11.

Escobar, Carlos, Luis Varela, Beatriz Palacios, et al.. (2021). Clinical characteristics, management, and one-year risk of complications among patients with heart failure with and without type 2 diabetes in Spain. Revista Clínica Española (English Edition). 222(4). 195–204. 6 indexed citations

12.

Escobar, Carlos, Beatriz Palacios, Margarita Capel, et al.. (2021). Epidemiology, clinical profile, management, and two-year risk complications among patients with chronic kidney disease in Spain. Nefrología. 41(6). 670–688. 12 indexed citations

13.

Escobar, Carlos, Luis Varela, Beatriz Palacios, et al.. (2020). Costs and healthcare utilisation of patients with heart failure in Spain. BMC Health Services Research. 20(1). 964–964. 49 indexed citations

14.

Botana, Manuel, Alberto Fernández‐Villar, Virginia Leiro, et al.. (2009). Intubación traqueal guiada por fibrobroncoscopio en pacientes con vía aérea difícil. Factores predictores del resultado. Medicina Intensiva. 33(2). 68–73. 1 indexed citations

15.

Pellat, Fernando Paz, José Cameselle‐Teijeiro, Joaquín Lado‐Abeal, et al.. (2008). Prevalence of mutations in TSHR, GNAS, PRKAR1A and RAS genes in a large series of toxic thyroid adenomas from Galicia, an iodine-deficient area in NW Spain. European Journal of Endocrinology. 159(5). 623–631. 47 indexed citations

16.

Pérez-Fernández, Román, et al.. (2007). Prevalence, awareness, treatment and control of hypertension in Galicia (Spain) and association with related diseases. Journal of Human Hypertension. 21(5). 366–373. 49 indexed citations

17.

Cameselle, José Manuel Sabucedo, Francisco Barreiro, Manuel Botana, et al.. (2006). Study of the prevalence and mechanisms of action of TSH receptor and Gs protein alfa-subunit mutations, in toxic multinodular goiter and toxic adenoma from Galicia (Spain). 11.

18.

Botana, Manuel, et al.. (1994). Influence of kidney or heart transplantation on the urinary excretion of epidermal growth factor. Transplant International. 7(2). 127–130. 3 indexed citations

19.

Botana, Manuel, L. Castillo, C. Pesquera, et al.. (1993). Lack of Effect of Octreotide on Parathyroid Hormone Levels and Urinary Excretion of Epidermal Growth Factor. Hormone and Metabolic Research. 25(1). 37–39. 4 indexed citations

20.

Amado, José, et al.. (1993). Low Levels of Intraplatelet cGMP in IDDM. Diabetes Care. 16(5). 809–811. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact